The inferior vena cava filters market was valued at US$502.35 million in 2017 and is expected to reach US$825.02 million by 2023 growing at a CAGR of 8.62% during the forecast period. An inferior vena cava filter (IVC) is a medical device that is implanted into the inferior vena cava in for deep venous thrombosis (DVT) or pulmonary embolism (PE). It is used in patients who are at high risk of developing a PE and cannot be sufficiently anticoagulated. They can either be permanent or retrievable; the latter though poses a challenge to the market as negligence in timely removal has been a concern. Factors driving the inferior vena cava filter are high increased research and development expenditures, growth in the cardiac devices market, rising healthcare spending in emerging economies and technology spill over in nascent markets. Geographically, North America and Europe dominate the IVC filters market while Asia Pacific is a region of high growth.
This section provides an anatomy of the research process followed for calculating market size and forecasts along with a list of the secondary data sources used and the primary inputs which were taken for data validation. It also provides an outline of the various segmentations which have been covered as part of the report.
In this section, the entire inferior vena cava filters market is explained along with the various drivers, restraints and opportunities. A product pipeline has been mentioned along with innovations in the market. Certain regulations specific to the industry are also listed out, followed by a detailed scenario analysis.
The Inferior Vena Cava Filters market has been segmented based on type and geography as below:
Europe Middle East and Africa
Middle East and Africa
The competitive intelligence section deals with major players in the market, their market shares, products, growth strategies, financials, and recent investments among others. Key industry players in the Inferior Vena Cava Filters market are ALN Medical Management, B. Braun, Boston Scientific, C.R. Bard, Cook Medical, and Cordis Corporation.